Vaccination against HPV: indications for women and the impact on the cervical screening programme

Authors

  • DAM Heideman,

    Corresponding author
    1. a Department of Pathology and b Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, the Netherlandsc Department of Woman and Baby, University Medical Centre Utrecht, Utrecht, the Netherlandsd Department of Obstetrics and Gynecology, Erasmus MC, University Hospital Rotterdam, Rotterdam, the Netherlands
      DAM Heideman, Department of Pathology, VU University Medical Centre, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. Email dam.heideman@vumc.nl
    Search for more papers by this author
  • a PJF Snijders,

    1. a Department of Pathology and b Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, the Netherlandsc Department of Woman and Baby, University Medical Centre Utrecht, Utrecht, the Netherlandsd Department of Obstetrics and Gynecology, Erasmus MC, University Hospital Rotterdam, Rotterdam, the Netherlands
    Search for more papers by this author
  • a J Berkhof,

    1. a Department of Pathology and b Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, the Netherlandsc Department of Woman and Baby, University Medical Centre Utrecht, Utrecht, the Netherlandsd Department of Obstetrics and Gynecology, Erasmus MC, University Hospital Rotterdam, Rotterdam, the Netherlands
    Search for more papers by this author
  • b RHM Verheijen,

    1. a Department of Pathology and b Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, the Netherlandsc Department of Woman and Baby, University Medical Centre Utrecht, Utrecht, the Netherlandsd Department of Obstetrics and Gynecology, Erasmus MC, University Hospital Rotterdam, Rotterdam, the Netherlands
    Search for more papers by this author
  • c TJM Helmerhorst,

    1. a Department of Pathology and b Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, the Netherlandsc Department of Woman and Baby, University Medical Centre Utrecht, Utrecht, the Netherlandsd Department of Obstetrics and Gynecology, Erasmus MC, University Hospital Rotterdam, Rotterdam, the Netherlands
    Search for more papers by this author
  • and d CJLM Meijer a

    1. a Department of Pathology and b Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, the Netherlandsc Department of Woman and Baby, University Medical Centre Utrecht, Utrecht, the Netherlandsd Department of Obstetrics and Gynecology, Erasmus MC, University Hospital Rotterdam, Rotterdam, the Netherlands
    Search for more papers by this author

DAM Heideman, Department of Pathology, VU University Medical Centre, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. Email dam.heideman@vumc.nl

Abstract

A novel approach for primary prevention of cervical cancer has become available by the discovery of efficient prophylactic human papillomavirus (HPV) vaccines based on virus-like particles. This review elaborates on the progress in the field of prophylactic HPV vaccination achieved in the past decade, provides indications for prophylactic HPV vaccination, and discusses the impact on public health and the current secondary prevention system. In summary, with current vaccines, effective prevention and control of cervical cancer within the next decades requires an integrated vaccination-screening approach, including routine prophylactic vaccination to young women and adapted cervical screening for older women (≥30 years).

Ancillary